Drugs / Hepatitis B recombinant vaccine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Procomvax | — | 2009-05-14 | europa.eu ↗ |
| Approved | EU (EMA) | Procomvax | — | 1999-05-07 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04326803 | Jun 2020 → Jun 2022 | hepatitis B virus infection | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepatitis B recombinant vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04326803 ↗ |
| Known as | Engerix-B vaccine | “Engerix-B vaccine” NCT04326803 ↗ |
| Modality | Vaccine | “recombinant hepatitis B vaccine” NCT04326803 ↗ |
| Route | Intramuscular | “intramuscular use” NCT04326803 ↗ |